Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Achillion Pharmaceuticals Inc patents


Recent patent applications related to Achillion Pharmaceuticals Inc. Achillion Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Achillion Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Achillion Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Achillion Pharmaceuticals Inc-related inventors


Compounds for treatment of immune inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d are provided comprising formula i, i″ and i′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

Amide compounds for treatment of immune and inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d are provided comprising formula i, i″ and i′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d are provided comprising formula i, i″ and i′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

Amino compounds for treatment of immune and inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d are provided comprising formula i, i″ and i′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

Amino compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is an amino substituent (r32) are provided. The inhibitors of factor d described herein reduce the excessive activation of complement.. ... Achillion Pharmaceuticals Inc

Alkyne compounds for treatment of complement mediated disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof, wherein r12 or r13 on the a group is an alkyne (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders

. . Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r11 on the a group is an aryl, heteroaryl or heterocycle (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

Compounds for treatment of complement mediated disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

Ether compounds for treatment of complement mediated disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is an ether (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

Combination drug treatment for hepatitis c infection

A method for the treatment of hepatitis c infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of compound (i), compound (ii), and compound (iii), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.. . ... Achillion Pharmaceuticals Inc

Combination therapy regimen for treatment of selected hcv genotypes

A method for the treatment of hepatitis c infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of compound (i), compound (ii), and compound (iii), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.. . ... Achillion Pharmaceuticals Inc

Combination drug treatment for hepatitis c infection

A composition, including a fixed dose composition, comprising compound (i), compound (ii), and compound (iii) for the treatment of hepatitis c, and methods of manufacture thereof.. . ... Achillion Pharmaceuticals Inc

Phosphonate compounds for treatment of complement mediated disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is a phosphonate (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

Factor d inhibitors useful for treating inflammatory disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

07/06/17 / #20170189410

Amino compounds for treatment of complement mediated disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof, wherein r12 or r13 on the a group is an amino substituent (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor d's ability to modulate the classical and lectin complement pathways. ... Achillion Pharmaceuticals Inc

03/30/17 / #20170087174

Combination therapy regimen for treatment of hcv

. . A composition, including a fixed dose composition, comprising compound (i), compound (ii), and compound (iii) for the treatment of hepatitis c, and methods of manufacture thereof.. . ... Achillion Pharmaceuticals Inc

03/09/17 / #20170066783

Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is an aryl, heteroaryl or heterocycle (r32) are provided. The inhibitors of factor d described herein reduce the excessive activation of complement.. ... Achillion Pharmaceuticals Inc

03/02/17 / #20170057993

Ether compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is an ether substituent (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

03/02/17 / #20170057983

Phosphonate compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is a phosphonate substituent (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

03/02/17 / #20170057950

Amide compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof wherein r12 or r13 on the a group is an amide substituent (r32) are provided. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc

03/02/17 / #20170056428

Compounds for the treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor d comprising formula i, or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target factor d and inhibit or regulate the complement cascade. ... Achillion Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Achillion Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Achillion Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###